Other groups requiring careful evaluation include: Patients with a history of pancreatitis a causal relationship between incretin-based therapies and pancreatitis has not been definitively established, but UK SmPCs advise caution in those with a prior history
Your provider may recommend temporarily reducing the dose, taking additional anti-nausea medication, or adjusting your titration schedule
In the SUSTAIN clinical trials, semaglutide OW achieved superior glycemic control and weight loss compared with several other classes of anti-diabetes medications (ADMs) [14,15,16,17,18], including canagliflozin, an SGLT2i [19]
Additionally, Rybelsus should be used with caution in people with severe digestive system problems or if you are pregnant or breastfeeding, unless advised otherwise by your doctor